Invent Medic’s new framework agreement for Efemia Bladder Support
With an impressive 300 per cent increase in sales in the first quarter, Invent Medic continues its upward trend. The company aims to maintain a high pace and recently signed framework agreements with five new regions regarding Efemia Bladder Support. CEO Anna Lindström says that the agreement clearly shows the appreciation that exists for the product.
Lund-based Invent Medic is a medical technology company that specialises in the development of innovative products in women’s health. The first product in the portfolio, Efemia Bladder Support, is an effective aid for women suffering from stress urinary incontinence. Efemia has been developed to give women the possibility of an active and carefree life by reducing or completely eliminating the symptoms of incontinence.
Invent Medic reported robust growth of 300 per cent in the first quarter, a success that can be attributed to a combination of the recently acquired FlowCup and the continued strong performance from Efemia Bladder Support. You can read more about the good development during Q1 here.
Framework agreements signed with five new regions
Even though the sales successes have been significant, Invent Medic sees no reason to slow down. The company recently announced that it had signed framework agreements with five new regions for Efemia – Dalarna, Sörmland, Uppsala, Västmanland and Örebro, also known as ‘femklövern’, (Eng: five-leaf clover). The agreement, which follows the completion of the public procurement, will effectively start in January 2024 and extend over a total contract period of a maximum of three years.
Following this agreement, Efemia Bladder Support will be available for prescription in 16 of Sweden’s 21 healthcare regions. The company sees it as an important step towards the long-term ambition to sign agreements with all Swedish regions.
“Five new regions at once, that’s a big one! We have worked methodically both before and during the procurement. The fact that we are now signing an agreement proves that our offer is attractive for healthcare. The work continues in these and other procured regions to train prescribers and healthcare professionals. Those who meet patients needs to feel safe with Efemia Bladder Support”, says Invent Medic’s CEO Anna Lindström in a comment to BioStock.
She emphasises that the framework agreement with ‘femklövern’ clearly shows that Efemia Bladder Support is a product that the healthcare system appreciates and wants to offer to women so that they can manage their stress urinary incontinence in a simple and smooth way.
Expects continued growth
According to Anna Lindström, the good sales development is not a coincidence, but the result of hard work and a committed team. At the same time, the positive response from customers has given the company a solid foundation to stand on. The expectation is that sales will continue to increase as the company is able to reach more potential customers.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
